20/20 Biolabs (AIDX) Competitors

$0.98 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$1.02 +0.04 (+4.08%)

As of 05/22/2026 07:59 PM Eastern

AIDX vs. CAST, BGSF, GMHS, BRAG, and ONMD

Should you buy 20/20 Biolabs stock or one of its competitors? MarketBeat compares 20/20 Biolabs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 20/20 Biolabs include FreeCast (Direct Listing) (CAST), BGSF (BGSF), Gamehaus (GMHS), Bragg Gaming Group (BRAG), and OneMedNet (ONMD). These companies are all part of the "business services" industry.

How does 20/20 Biolabs compare to FreeCast (Direct Listing)?

FreeCast (Direct Listing) (NASDAQ:CAST) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
FreeCast (Direct Listing)	$565.17K	73.88	N/A	N/A	N/A
20/20 Biolabs	$2.05M	5.09	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
FreeCast (Direct Listing)	N/A	N/A	N/A
20/20 Biolabs	N/A	N/A	N/A

0.0% of FreeCast (Direct Listing) shares are owned by institutional investors. 17.5% of FreeCast (Direct Listing) shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

FreeCast (Direct Listing) currently has a consensus price target of $6.00, indicating a potential upside of 494.06%. 20/20 Biolabs has a consensus price target of $5.00, indicating a potential upside of 410.20%. Given FreeCast (Direct Listing)'s stronger consensus rating and higher possible upside, research analysts clearly believe FreeCast (Direct Listing) is more favorable than 20/20 Biolabs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
FreeCast (Direct Listing)	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, 20/20 Biolabs had 3 more articles in the media than FreeCast (Direct Listing). MarketBeat recorded 4 mentions for 20/20 Biolabs and 1 mentions for FreeCast (Direct Listing). 20/20 Biolabs' average media sentiment score of 0.27 beat FreeCast (Direct Listing)'s score of 0.00 indicating that 20/20 Biolabs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
FreeCast (Direct Listing)	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
20/20 Biolabs	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

FreeCast (Direct Listing) beats 20/20 Biolabs on 5 of the 8 factors compared between the two stocks.

How does 20/20 Biolabs compare to BGSF?

20/20 Biolabs (NASDAQ:AIDX) and BGSF (NYSE:BGSF) are both small-cap business services companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

37.2% of BGSF shares are owned by institutional investors. 8.0% of BGSF shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, 20/20 Biolabs had 3 more articles in the media than BGSF. MarketBeat recorded 4 mentions for 20/20 Biolabs and 1 mentions for BGSF. 20/20 Biolabs' average media sentiment score of 0.27 beat BGSF's score of 0.00 indicating that 20/20 Biolabs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
20/20 Biolabs	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BGSF	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

20/20 Biolabs has higher earnings, but lower revenue than BGSF.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$2.05M	5.09	N/A	N/A	N/A
BGSF	$93.31M	0.60	-$11.43M	-$1.00	N/A

20/20 Biolabs currently has a consensus price target of $5.00, indicating a potential upside of 410.20%. Given 20/20 Biolabs' higher possible upside, equities research analysts clearly believe 20/20 Biolabs is more favorable than BGSF.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BGSF	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

20/20 Biolabs has a net margin of 0.00% compared to BGSF's net margin of -11.98%. 20/20 Biolabs' return on equity of 0.00% beat BGSF's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
BGSF	-11.98%	-18.91%	-12.30%

Summary

20/20 Biolabs beats BGSF on 8 of the 13 factors compared between the two stocks.

How does 20/20 Biolabs compare to Gamehaus?

20/20 Biolabs (NASDAQ:AIDX) and Gamehaus (NASDAQ:GMHS) are both small-cap business services companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

Gamehaus has higher revenue and earnings than 20/20 Biolabs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$2.05M	5.09	N/A	N/A	N/A
Gamehaus	$118.05M	0.46	$3.96M	$0.09	11.22

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
Gamehaus	N/A	N/A	N/A

In the previous week, 20/20 Biolabs had 3 more articles in the media than Gamehaus. MarketBeat recorded 4 mentions for 20/20 Biolabs and 1 mentions for Gamehaus. 20/20 Biolabs' average media sentiment score of 0.27 beat Gamehaus' score of 0.00 indicating that 20/20 Biolabs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
20/20 Biolabs	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gamehaus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

63.7% of Gamehaus shares are held by institutional investors. 27.7% of Gamehaus shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

20/20 Biolabs presently has a consensus target price of $5.00, suggesting a potential upside of 410.20%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, research analysts clearly believe 20/20 Biolabs is more favorable than Gamehaus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gamehaus	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

20/20 Biolabs beats Gamehaus on 6 of the 9 factors compared between the two stocks.

How does 20/20 Biolabs compare to Bragg Gaming Group?

Bragg Gaming Group (NASDAQ:BRAG) and 20/20 Biolabs (NASDAQ:AIDX) are both small-cap business services companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends.

Bragg Gaming Group currently has a consensus price target of $5.00, indicating a potential upside of 203.03%. 20/20 Biolabs has a consensus price target of $5.00, indicating a potential upside of 410.20%. Given 20/20 Biolabs' stronger consensus rating and higher probable upside, analysts plainly believe 20/20 Biolabs is more favorable than Bragg Gaming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bragg Gaming Group	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, 20/20 Biolabs had 4 more articles in the media than Bragg Gaming Group. MarketBeat recorded 4 mentions for 20/20 Biolabs and 0 mentions for Bragg Gaming Group. 20/20 Biolabs' average media sentiment score of 0.27 beat Bragg Gaming Group's score of 0.00 indicating that 20/20 Biolabs is being referred to more favorably in the news media.

Company	Overall Sentiment
Bragg Gaming Group	Neutral
20/20 Biolabs	Neutral

20/20 Biolabs has lower revenue, but higher earnings than Bragg Gaming Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bragg Gaming Group	$119.98M	0.34	-$9.18M	-$0.31	N/A
20/20 Biolabs	$2.05M	5.09	N/A	N/A	N/A

20/20 Biolabs has a net margin of 0.00% compared to Bragg Gaming Group's net margin of -6.27%. 20/20 Biolabs' return on equity of 0.00% beat Bragg Gaming Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bragg Gaming Group	-6.27%	-10.65%	-6.92%
20/20 Biolabs	N/A	N/A	N/A

4.0% of Bragg Gaming Group shares are held by institutional investors. 26.4% of Bragg Gaming Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

20/20 Biolabs beats Bragg Gaming Group on 9 of the 12 factors compared between the two stocks.

How does 20/20 Biolabs compare to OneMedNet?

20/20 Biolabs (NASDAQ:AIDX) and OneMedNet (NASDAQ:ONMD) are both small-cap business services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

In the previous week, 20/20 Biolabs and 20/20 Biolabs both had 4 articles in the media. OneMedNet's average media sentiment score of 1.12 beat 20/20 Biolabs' score of 0.27 indicating that OneMedNet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
20/20 Biolabs	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OneMedNet	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

20/20 Biolabs presently has a consensus price target of $5.00, indicating a potential upside of 410.20%. Given 20/20 Biolabs' stronger consensus rating and higher possible upside, equities analysts plainly believe 20/20 Biolabs is more favorable than OneMedNet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
20/20 Biolabs	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
OneMedNet	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.0% of OneMedNet shares are owned by institutional investors. 46.2% of OneMedNet shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

20/20 Biolabs has a net margin of 0.00% compared to OneMedNet's net margin of -254.13%.

Company	Net Margins	Return on Equity	Return on Assets
20/20 Biolabs	N/A	N/A	N/A
OneMedNet	-254.13%	N/A	-383.90%

20/20 Biolabs has higher revenue and earnings than OneMedNet.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
20/20 Biolabs	$2.05M	5.09	N/A	N/A	N/A
OneMedNet	$1.36M	36.15	-$2.80M	-$0.07	N/A

Summary

20/20 Biolabs beats OneMedNet on 6 of the 10 factors compared between the two stocks.

Get 20/20 Biolabs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIDX vs. The Competition

Export

Metric	20/20 Biolabs	Services – Research, Development, Testing Labs Industry	Services Sector	NASDAQ Exchange
Market Cap	$10.40M	$10.06M	$978.18M	$12.34B
Dividend Yield	N/A	N/A	5.12%	5.28%
P/E Ratio	N/A	N/A	9.25	25.66
Price / Sales	5.09	3.18	36.53	86.31
Price / Cash	N/A	N/A	381.82	56.67
Price / Book	N/A	0.22	4.35	7.14
Net Income	N/A	-$15.16M	-$6.42M	$335.98M
7 Day Performance	-26.87%	-11.06%	3.07%	4.15%
1 Month Performance	-40.24%	-22.31%	-5.06%	2.54%
1 Year Performance	N/A	N/A	48.28%	35.06%

20/20 Biolabs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIDX 20/20 Biolabs	N/A	$0.98 flat	$5.00 +410.2%	N/A	$10.40M	$2.05M	N/A	14	Earnings Report Gap Up High Trading Volume
CAST FreeCast (Direct Listing)	2.7739 of 5 stars	$1.33 -7.6%	$6.00 +350.8%	N/A	$55.57M	$616.15K	N/A	48	Gap Up
BGSF BGSF	0.7183 of 5 stars	$5.18 +0.4%	N/A	+18.4%	$55.53M	$93.31M	N/A	400
GMHS Gamehaus	0.8747 of 5 stars	$0.95 -8.8%	N/A	-21.7%	$50.84M	$113.59M	10.54	N/A	Gap Down
BRAG Bragg Gaming Group	2.6358 of 5 stars	$1.77 +7.9%	$5.00 +182.5%	-62.1%	$44.32M	$119.98M	N/A	290	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIDX) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

20/20 Biolabs (AIDX) Competitors

AIDX vs. CAST, BGSF, GMHS, BRAG, and ONMD

How does 20/20 Biolabs compare to FreeCast (Direct Listing)?

Summary

How does 20/20 Biolabs compare to BGSF?

Summary

How does 20/20 Biolabs compare to Gamehaus?

Summary

How does 20/20 Biolabs compare to Bragg Gaming Group?

Summary

How does 20/20 Biolabs compare to OneMedNet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIDX vs. The Competition

20/20 Biolabs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

20/20 Biolabs (AIDX) Competitors

AIDX vs. CAST, BGSF, GMHS, BRAG, and ONMD

How does 20/20 Biolabs compare to FreeCast (Direct Listing)?

Which has higher valuation & earnings, CAST or AIDX?

Is CAST or AIDX more profitable?

Do insiders & institutionals have more ownership in CAST or AIDX?

Do analysts prefer CAST or AIDX?

Does the media prefer CAST or AIDX?

Summary

How does 20/20 Biolabs compare to BGSF?

Do insiders and institutionals believe in AIDX or BGSF?

Does the media refer more to AIDX or BGSF?

Which has higher earnings and valuation, AIDX or BGSF?

Do analysts rate AIDX or BGSF?

Is AIDX or BGSF more profitable?

Summary

How does 20/20 Biolabs compare to Gamehaus?

Which has stronger earnings & valuation, AIDX or GMHS?

Is AIDX or GMHS more profitable?

Does the media refer more to AIDX or GMHS?

Do insiders and institutionals have more ownership in AIDX or GMHS?

Do analysts prefer AIDX or GMHS?

Summary

How does 20/20 Biolabs compare to Bragg Gaming Group?

Do analysts rate BRAG or AIDX?

Does the media prefer BRAG or AIDX?

Which has higher earnings and valuation, BRAG or AIDX?

Is BRAG or AIDX more profitable?

Do insiders & institutionals believe in BRAG or AIDX?

Summary

How does 20/20 Biolabs compare to OneMedNet?

Does the media refer more to AIDX or ONMD?

Do analysts prefer AIDX or ONMD?

Do insiders and institutionals have more ownership in AIDX or ONMD?

Is AIDX or ONMD more profitable?

Which has stronger valuation & earnings, AIDX or ONMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIDX vs. The Competition

20/20 Biolabs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools